Skip to main content
aap Implantate AG logo

aap Implantate AG — Investor Relations & Filings

Ticker · AAQ1 ISIN · DE000A3H2101 LEI · 39120001TRQTQ01LPP57 F Manufacturing
Open in API
Filings indexed 854 across all filing types
Latest filing 2023-03-30 Director's Dealing
Country DE Germany
Listing F AAQ1

About aap Implantate AG

https://www.aap.de/

aap Implantate AG is a medical technology company that operates as a pure player in the field of traumatology. The company develops, manufactures, and markets implants for the treatment of bone fractures. Its core product is the LOQTEQ® system, a comprehensive portfolio of anatomical plates and screws featuring a patented technology that combines fracture compression with angle-stable locking. This titanium-based system is designed to cover a broad spectrum of indications in upper and lower extremity trauma surgery. In addition to its established product line, aap is developing next-generation platform technologies, including antibacterial silver-coated implants to reduce infection risk and resorbable magnesium implants intended to eliminate the need for secondary removal surgeries.

Recent filings

Filing Released Lang Actions
aap Implantate AG: Merval AG, Subscription of shares as part of the private placement in connection with a rights issue capital increase
Director's Dealing Classification · 99% confidence The document is explicitly titled 'Directors’ Dealings' and contains a section detailing 'Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them'. It lists the name of the associated person (Nathalie Krebs, Member of the administrative or supervisory body) and details of a transaction involving the subscription of shares. This directly matches the definition for Director's Dealing (DIRS). Although it mentions a capital increase, the primary focus and structure of the filing is the insider transaction disclosure.
2023-03-30 English
aap Implantate AG: Agnieszka Mierzejewska, Subscription of shares as part of the private placement in connection with a rights issue capital increase
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and details a transaction ('Subscription of shares') made by a 'person discharging managerial responsibilities' (Agnieszka Mierzejewska, Member of the managing body). This directly corresponds to the definition of Director's Dealing. The filing type code for this is DIRS.
2023-03-30 English
Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a short announcement from aap Implantate AG, dated March 29, 2023, titled 'Total Voting Rights Announcement'. It explicitly states the 'Publication of total number of voting rights' and details a capital measure (Other capital measure under Sec. 41 para. 1 WpHG) resulting in a new total of 8,954,953 voting rights. This content directly relates to changes in the company's capital structure and the resulting voting power, which aligns best with the 'Share Issue/Capital Change' definition (SHA). Although it mentions German securities law (WpHG), the core subject is the change in the total number of shares/voting rights, not a general regulatory filing (RNS) or a dividend announcement (DIV). It is not a full report, so RPA/RNS is less specific than SHA.
2023-03-29 English
aap receives US-American clearance (FDA) for polyaxial LOQTEQ VA Elbow system; launch planned for Q4 2023
Regulatory Filings Classification · 100% confidence The document is a news release dated March 21, 2023, announcing that aap Implantate AG received US-American FDA clearance for a new medical device system (LOQTEQ® VA Elbow system) and plans a market launch in Q4 2023. It uses keywords like "EQS-News," "Regulatory Approval/Market Launch," and discusses product details and future plans. This type of announcement, focusing on a specific regulatory milestone (FDA clearance) and immediate market plans, is best classified as a general Regulatory Filing or News Release, as it doesn't fit the specific definitions for Earnings Release (ER), Interim Report (IR), or Capital Update (CAP). Since it is a specific regulatory/market event announcement disseminated via a news service (EQS), and it is not a full financial report, the most appropriate general category is Regulatory Filings (RNS), which serves as a fallback for specific regulatory news that isn't covered by other codes like DIRS or DIV. Given the content is a specific regulatory event announcement, RNS is the best fit among the available options, although it is highly specific news.
2023-03-21 English
Result of the capital increase with subscription rights: capital measure fully subscribed; issue of 2.4 million new shares leads to gross issue proceeds of around EUR 3.3 million
Share Issue/Capital Change Classification · 99% confidence The document is an 'Ad-hoc' announcement dated March 15, 2023, detailing the 'Result of the capital increase with subscription rights' and reporting gross issue proceeds of EUR 3.3 million from issuing new shares. This content directly relates to fundraising, financing activities, and changes in the capital structure. This aligns perfectly with the definition for Capital/Financing Update (CAP). Although it involves issuing shares (SHA), the primary focus and context are the successful completion and proceeds of a financing measure, making CAP the most specific fit.
2023-03-15 English
aap Implantate AG: Langner Asset Management GmbH, Granting of 10,000 subscription rights within a capital increase with subsription rights
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains a 'Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them'. It details a transaction involving a person closely associated with a member of the administrative body (Marc Langner) and the granting of subscription rights. This directly matches the definition for Director's Dealing (DIRS). Although it involves a capital increase aspect, the primary focus and structure are that of an insider transaction disclosure.
2023-03-01 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.